دورية أكاديمية
أعرض في EDS

The interplay between prolactin and cardiovascular disease.

التفاصيل البيبلوغرافية
العنوان: The interplay between prolactin and cardiovascular disease.
المؤلفون: Glezer A; Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School, São Paulo, SP, Brazil.; Laboratory of Cellular and Molecular Endocrinology LIM-25, University of Sao Paulo Medical School, São Paulo, SP, Brazil., Santana MR; Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School, São Paulo, SP, Brazil., Bronstein MD; Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School, São Paulo, SP, Brazil.; Laboratory of Cellular and Molecular Endocrinology LIM-25, University of Sao Paulo Medical School, São Paulo, SP, Brazil., Donato J Jr; Department of Physiology and Biophysics, Instituto de Ciencias Biomedicas, Universidade de Sao Paulo, Sao Paulo, SP, Brazil., Jallad RS; Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School, São Paulo, SP, Brazil.; Laboratory of Cellular and Molecular Endocrinology LIM-25, University of Sao Paulo Medical School, São Paulo, SP, Brazil.
المصدر: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Jan 10; Vol. 13, pp. 1018090. Date of Electronic Publication: 2023 Jan 10 (Print Publication: 2022).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: Hyperprolactinemia*/complications , Prolactinoma*/complications , Prolactinoma*/drug therapy , Cardiovascular Diseases*/etiology , Pituitary Neoplasms*/metabolism , Hypogonadism*, Male ; Humans ; Female ; Prolactin/metabolism ; Carotid Intima-Media Thickness ; Dopamine Agonists ; Cholesterol, LDL ; Homocysteine
مستخلص: Hyperprolactinemia can be caused by several conditions and its effects on the hypothalamic-pituitary-gonadal axis are understood in more detail. Nevertheless, in recent decades, other metabolic effects have been studied and data pointed to a potential increased cardiovascular disease (CVD) risk. A recent study showed a decrease in total and LDL- cholesterol only in men with prolactinoma treated with dopamine agonists (DA) supporting the previous results of a population study with increased CVD risk in men harboring prolactinoma. However, other population studies did not find a correlation between prolactin (PRL) levels and CVD risk or mortality. There is also data pointing to an increase in high-density lipoprotein levels, and decreases in triglycerides, carotid-intima-media thickness, C-reactive protein, and homocysteine levels in patients with prolactinoma on DA treatment. PRL was also implicated in endothelial dysfunction in pre and postmenopausal women. Withdrawal of DA resulted in negative changes in vascular parameters and an increase in plasma fibrinogen. It has been shown that PRL levels were positively correlated with blood pressure and inversely correlated with dilatation of the brachial artery and insulin sensitivity, increased homocysteine levels, and elevated D-dimer levels. Regarding possible mechanisms for the association between hyperprolactinemia and CVD risk, they include a possible direct effect of PRL, hypogonadism, and even effects of DA treatment, independently of changes in PRL levels. In conclusion, hyperprolactinemia seems to be associated with impaired endothelial function and DA treatment could improve CVD risk. More studies evaluating CVD risk in hyperprolactinemic patients are important to define a potential indication of treatment beyond hypogonadism.
Competing Interests: The authors declare that this review was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023 Glezer, Santana, Bronstein, Donato and Jallad.)
References: J Am Heart Assoc. 2012 Oct;1(5):e002279. (PMID: 23316290)
Pituitary. 2014 Jun;17(3):232-9. (PMID: 23756783)
J Clin Endocrinol Metab. 2006 Mar;91(3):1048-55. (PMID: 16384849)
Card Electrophysiol Clin. 2015 Jun;7(2):309-17. (PMID: 26002395)
Clin J Am Soc Nephrol. 2012 Feb;7(2):207-15. (PMID: 22193237)
Int J Eat Disord. 2022 Nov;55(11):1421-1458. (PMID: 35841198)
Gen Comp Endocrinol. 2020 Nov 1;298:113589. (PMID: 32827513)
J Clin Endocrinol Metab. 2008 Jul;93(7):2492-9. (PMID: 18460570)
Front Endocrinol (Lausanne). 2017 Dec 11;8:342. (PMID: 29321761)
J Neuroendocrinol. 2018 Jan;30(1):. (PMID: 29224246)
Autoimmun Rev. 2009 Sep;9(1):23-7. (PMID: 19248843)
Hum Reprod. 1999 Feb;14(2):285-7. (PMID: 10099964)
Mol Cell Endocrinol. 2005 Mar 31;232(1-2):9-19. (PMID: 15737464)
J Clin Pharmacol. 2019 Jan;59(1):83-89. (PMID: 30129670)
Diabetes Care. 1997 Nov;20(11):1697-701. (PMID: 9353611)
Endocrinology. 1999 Feb;140(2):1026-9. (PMID: 9927340)
Diabetes Metab Res Rev. 2011 Sep;27(6):564-74. (PMID: 21557442)
Pediatr Res. 1993 Nov;34(5):642-5. (PMID: 8284103)
Diabetes Care. 2013 Jul;36(7):1974-80. (PMID: 23340889)
Basic Clin Pharmacol Toxicol. 2015 Mar;116(3):251-6. (PMID: 25123447)
Pak J Med Sci. 2019 Jul-Aug;35(4):1122-1127. (PMID: 31372154)
Horm Metab Res. 2019 Nov;51(11):709-713. (PMID: 31683340)
Int J Androl. 2011 Jun;34(3):217-24. (PMID: 20522124)
Lancet. 1971 Aug 14;2(7720):352-4. (PMID: 4105050)
J Neuroendocrinol. 2003 Nov;15(11):1046-53. (PMID: 14622434)
Endocrinol Metab Clin North Am. 2015 Mar;44(1):71-8. (PMID: 25732643)
Clin Endocrinol (Oxf). 2010 Oct;73(4):502-7. (PMID: 20039901)
Endocrinology. 1995 Sep;136(9):4092-8. (PMID: 7649117)
Endocrinology. 2001 Jul;142(7):2805-10. (PMID: 11415999)
Front Endocrinol (Lausanne). 2021 Nov 30;12:769744. (PMID: 34917030)
Diabetes Obes Metab. 2011 Oct;13(10):880-4. (PMID: 21569186)
J Clin Endocrinol Metab. 2003 Feb;88(2):689-96. (PMID: 12574200)
Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12538-12543. (PMID: 27791173)
J Clin Endocrinol Metab. 2003 Apr;88(4):1804-8. (PMID: 12679477)
FASEB J. 2020 Mar;34(3):3902-3914. (PMID: 31944423)
Medicine (Baltimore). 2016 Oct;95(40):e4818. (PMID: 27749534)
Diabetes Obes Metab. 2021 Jan;23(1):58-67. (PMID: 32869474)
Neuroendocrinology. 2012;95(4):332-43. (PMID: 22441304)
J Endocrinol. 2015 Aug;226(2):T101-22. (PMID: 26101377)
Horm Metab Res. 2008 Jul;40(7):442-5. (PMID: 18401833)
J Clin Endocrinol Metab. 2021 Sep 27;106(10):2949-2961. (PMID: 34131733)
FASEB J. 2012 Sep;26(9):3728-37. (PMID: 22637534)
Front Horm Res. 2018;49:29-47. (PMID: 29894997)
Int J Endocrinol. 2020 Jun 22;2020:9524839. (PMID: 32655635)
Endocrinol Diabetes Metab. 2019 Nov 13;3(1):e00101. (PMID: 31922028)
Cell Metab. 2009 Aug;10(2):89-98. (PMID: 19656487)
Brain Res. 2010 Sep 2;1350:65-70. (PMID: 20417193)
Endocrinology. 2007 Aug;148(8):4080-90. (PMID: 17463060)
Cancers (Basel). 2021 May 06;13(9):. (PMID: 34066328)
Neuroimage Clin. 2022;33:102870. (PMID: 34872017)
Pituitary. 2020 Jun;23(3):307-313. (PMID: 32274622)
Endocrinology. 1999 Nov;140(11):5149-53. (PMID: 10537143)
Anatol J Cardiol. 2016 Jun;16(6):440-7. (PMID: 26680550)
Biochem Biophys Res Commun. 2004 Nov 5;324(1):355-9. (PMID: 15465026)
Clin Endocrinol (Oxf). 2018 Jan;88(1):71-76. (PMID: 29044586)
J Assoc Physicians India. 2017 Mar;65(3):34-39. (PMID: 28462541)
J Endocrinol Invest. 2008 Nov;31(11):985-90. (PMID: 19169054)
Cardiovasc Ther. 2015 Oct;33(5):282-7. (PMID: 26146893)
Sci Rep. 2015 Jun 12;5:11283. (PMID: 26066863)
Int J Neuropsychopharmacol. 2015 Feb 25;18(7):pyv014. (PMID: 25716779)
Exp Neurol. 2019 Oct;320:113006. (PMID: 31279911)
Brain Res. 2000 Jun 23;868(2):306-14. (PMID: 10854583)
J Diabetes Investig. 2017 Sep;8(5):697-700. (PMID: 28129477)
Ann Intern Med. 1989 Aug 15;111(4):288-92. (PMID: 2757313)
Endocr Rev. 1998 Jun;19(3):225-68. (PMID: 9626554)
Eur J Pharmacol. 1992 Apr 10;225(4):351-4. (PMID: 1499663)
Metab Brain Dis. 2017 Feb;32(1):155-161. (PMID: 27525431)
Clin Endocrinol (Oxf). 2013 Dec;79(6):845-52. (PMID: 23506485)
Eur Heart J. 2014 May;35(18):1215-21. (PMID: 22843444)
Eur J Endocrinol. 2002 Jul;147(1):77-84. (PMID: 12088923)
Nutr Metab (Lond). 2008 Dec 01;5:35. (PMID: 19046419)
J Clin Ultrasound. 2021 Oct;49(8):870-877. (PMID: 34131923)
Clin Endocrinol (Oxf). 2007 Dec;67(6):845-52. (PMID: 17645576)
Circulation. 2010 Apr 6;121(13):1465-73. (PMID: 20308616)
Niger J Clin Pract. 2021 Feb;24(2):213-219. (PMID: 33605911)
Pituitary. 2020 Feb;23(1):58-64. (PMID: 31686376)
J Am Coll Cardiol. 2022 Apr 5;79(13):1266-1269. (PMID: 35361349)
Neth Heart J. 2017 Apr;25(4):231-242. (PMID: 28194698)
Int J Mol Sci. 2022 Aug 09;23(16):. (PMID: 36012132)
Lancet. 2001 Feb 3;357(9253):354-7. (PMID: 11210998)
Endocrinology. 2012 Jul;153(7):3100-10. (PMID: 22547568)
Neuroendocrinology. 2013;98(4):299-310. (PMID: 24355865)
J Hypertens. 2010 Jul;28(7):1400-5. (PMID: 20453663)
Biochem Biophys Res Commun. 2005 Jun 17;331(4):1120-6. (PMID: 15882993)
Expert Rev Endocrinol Metab. 2018 Mar;13(2):99-106. (PMID: 30058862)
Endocr Pract. 2014 May;20(5):447-51. (PMID: 24325995)
Eur Heart J. 2017 Sep 14;38(35):2671-2679. (PMID: 28934837)
J Am Heart Assoc. 2016 Feb 23;5(2):. (PMID: 26908403)
Pituitary. 2011 Sep;14(3):199-207. (PMID: 21128120)
Endokrynol Pol. 2019;70(4):336-341. (PMID: 30845340)
J Endocrinol. 2016 Jul;230(1):157-69. (PMID: 27154336)
Diabetologia. 2018 Dec;61(12):2549-2560. (PMID: 30306190)
Brain Res. 1996 Aug 5;729(1):75-81. (PMID: 8874878)
Metabolism. 1976 May;25(5):509-16. (PMID: 1263843)
Diabetes Res Clin Pract. 2020 Aug;166:108247. (PMID: 32505717)
Diabetologia. 1977 Apr;13(2):99-104. (PMID: 852641)
J Endocrinol. 2011 Feb;208(2):107-17. (PMID: 21068074)
Diabetol Metab Syndr. 2015 Nov 14;7:99. (PMID: 26583049)
Endocrinology. 2002 Apr;143(4):1378-85. (PMID: 11897695)
Front Endocrinol (Lausanne). 2016 Mar 30;7:25. (PMID: 27065946)
Acta Diabetol. 2014 Feb;51(1):71-8. (PMID: 23836327)
J Neuroendocrinol. 2020 Nov;32(11):e12888. (PMID: 33463813)
Horm Metab Res. 2017 Jun;49(6):411-417. (PMID: 28437810)
Arch Gynecol Obstet. 1988;243(2):83-90. (PMID: 3401043)
Eur J Endocrinol. 2003 Sep;149(3):187-93. (PMID: 12943520)
Endocr Connect. 2019 Oct;8(10):1395-1404. (PMID: 31518995)
Cardiovasc Diabetol. 2018 Aug 31;17(1):122. (PMID: 30170598)
J Clin Endocrinol Metab. 2004 Sep;89(9):4445-9. (PMID: 15356045)
J Clin Endocrinol Metab. 2022 Aug 18;107(9):2652-2665. (PMID: 35666146)
Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H551-69. (PMID: 18083900)
Nature. 2022 Aug;608(7922):374-380. (PMID: 35831501)
Klin Wochenschr. 1987 Jun 1;65(11):516-9. (PMID: 3613464)
J Clin Endocrinol Metab. 2011 Feb;96(2):273-88. (PMID: 21296991)
Diabetes Care. 2000 Aug;23(8):1154-61. (PMID: 10937514)
Diabetes Metab Syndr. 2019 May - Jun;13(3):1765-1767. (PMID: 31235091)
Hypertension. 2013 May;61(5):1118-25. (PMID: 23460287)
Exp Clin Endocrinol Diabetes. 2021 Jan;129(1):7-13. (PMID: 31185509)
Clin Endocrinol (Oxf). 1982 Apr;16(4):383-90. (PMID: 7047001)
Clin Endocrinol (Oxf). 2006 Apr;64(4):366-70. (PMID: 16584506)
Circ Res. 2016 May 27;118(11):1723-35. (PMID: 27230638)
Mol Cell Endocrinol. 2007 Jan 15;263(1-2):120-33. (PMID: 17081683)
BMC Endocr Disord. 2013 Mar 21;13:12. (PMID: 23517652)
Hypertension. 2009 Jul;54(1):98-105. (PMID: 19451414)
Kardiologiia. 1986 May;26(5):64-7. (PMID: 3735922)
Neuroscience. 2016 Jun 14;325:175-87. (PMID: 27038750)
Circulation. 2016 Apr 5;133(14):1397-409. (PMID: 27045128)
Trends Endocrinol Metab. 2020 Apr;31(4):276-286. (PMID: 32044206)
PLoS One. 2017 Apr 6;12(4):e0175204. (PMID: 28384295)
Pituitary. 2009;12(2):96-104. (PMID: 18338266)
Jpn J Med. 1985 Feb;24(1):19-23. (PMID: 3889434)
Obesity (Silver Spring). 2011 Apr;19(4):800-5. (PMID: 20559294)
Am J Cardiol. 2019 Oct 15;124(8):1207-1212. (PMID: 31409451)
Circ Cardiovasc Genet. 2009 Aug;2(4):389-95. (PMID: 20031611)
Clin Endocrinol (Oxf). 1998 May;48(5):547-53. (PMID: 9666865)
Front Endocrinol (Lausanne). 2020 Feb 27;11:83. (PMID: 32180760)
Endocr Res. 2016 Aug;41(3):200-6. (PMID: 26864960)
Neuroendocrinology. 2015;101(1):66-81. (PMID: 25592453)
BMC Endocr Disord. 2021 Apr 26;21(1):81. (PMID: 33902531)
Endocr J. 2006 Aug;53(4):555-62. (PMID: 16849835)
Obes Res. 2003 Feb;11(2):311-2. (PMID: 12582229)
Eur J Endocrinol. 2020 Sep;183(3):307-316. (PMID: 32570208)
JAMA Intern Med. 2018 Mar 1;178(3):328-337. (PMID: 29340577)
Front Endocrinol (Lausanne). 2022 Jun 10;13:883092. (PMID: 35757410)
Front Endocrinol (Lausanne). 2021 Nov 24;12:749050. (PMID: 34899599)
Physiol Rev. 1998 Jan;78(1):189-225. (PMID: 9457173)
Endocr Connect. 2017 Nov;6(8):580-588. (PMID: 28954743)
J Am Coll Cardiol. 2019 Nov 19;74(20):2529-2532. (PMID: 31727292)
Brain Sci. 2022 Apr 08;12(4):. (PMID: 35448017)
Eur J Endocrinol. 2003 Mar;148(3):325-31. (PMID: 12611613)
Physiol Behav. 2020 Sep 1;223:112986. (PMID: 32492498)
Endocrine. 2013 Aug;44(1):193-9. (PMID: 23233277)
Endocr Connect. 2021 Apr 29;10(4):484-491. (PMID: 33794504)
Endocrinology. 2007 Dec;148(12):5977-83. (PMID: 17872372)
Cureus. 2021 Sep 8;13(9):e17824. (PMID: 34660034)
Diabetes Care. 2016 Jul;39(7):1250-8. (PMID: 27208323)
Nutrients. 2022 Sep 16;14(18):. (PMID: 36145208)
Cureus. 2022 Apr 1;14(4):e23721. (PMID: 35509763)
Genet Test Mol Biomarkers. 2013 Jul;17(7):567-71. (PMID: 23651351)
Sci Transl Med. 2018 May 23;10(442):. (PMID: 29794060)
Pituitary. 2009;12(4):330-4. (PMID: 19408128)
Chronobiol Int. 1993 Aug;10(4):244-58. (PMID: 8403068)
J Card Fail. 2009 Oct;15(8):645-50. (PMID: 19786252)
Am J Physiol. 1989 Jan;256(1 Pt 2):R276-80. (PMID: 2912221)
Pharmacopsychiatry. 2000 May;33(3):81-8. (PMID: 10855458)
Neuroendocrinology. 2000 Jan;71(1):68-78. (PMID: 10644901)
Eur Heart J. 2018 Sep 7;39(34):3165-3241. (PMID: 30165544)
Clin Endocrinol (Oxf). 1999 Feb;50(2):271. (PMID: 10396373)
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. (PMID: 33309175)
Med Hypotheses. 2015 Apr;84(4):321-6. (PMID: 25649851)
Am J Physiol Endocrinol Metab. 2016 Dec 1;311(6):E974-E988. (PMID: 27802964)
Endocrinology. 2017 Jan 1;158(1):56-68. (PMID: 27805870)
Trends Endocrinol Metab. 2006 Apr;17(3):110-6. (PMID: 16517173)
Am J Epidemiol. 2016 Aug 15;184(4):295-301. (PMID: 27466075)
فهرسة مساهمة: Keywords: cardiovascular risk; dopaminergic agonist; dyslipidemia; hyperglycemia; metabolic syndrome; prolactin; prolactinoma; systemic arterial hypertension
المشرفين على المادة: 9002-62-4 (Prolactin)
0 (Dopamine Agonists)
0 (Cholesterol, LDL)
0LVT1QZ0BA (Homocysteine)
تواريخ الأحداث: Date Created: 20230127 Date Completed: 20230130 Latest Revision: 20230208
رمز التحديث: 20230208
مُعرف محوري في PubMed: PMC9871591
DOI: 10.3389/fendo.2022.1018090
PMID: 36704037
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-2392
DOI:10.3389/fendo.2022.1018090